These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings.

Benzinga • 19 hours ago

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing

GlobeNewsWire • Feb 2, 2026

Regeneron: Expect Double-Digit Growth In 2026

Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term growth and mitigate post-exclusivity risks. Eylea's decline is moderating, aided by increased patient support and anticipated label expansions.

Seeking Alpha • Jan 31, 2026

Regeneron beats quarterly profit estimates on Dupixent strength

U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.

Reuters • Jan 30, 2026

Regeneron bets added cholesterol benefit will help its obesity drug stand out

Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly crowded obesity market.

Reuters • Jan 30, 2026

Regeneron Handily Beat Fourth-Quarter Forecasts — Here's Why Shares Fell

Regeneron stock took a hit early Friday on its higher-than-expected 2026 cost outlook following a fourth-quarter beat.

Investors Business Daily • Jan 30, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript

Seeking Alpha • Jan 30, 2026

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business update.

GlobeNewsWire • Jan 30, 2026

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.

Benzinga • Jan 30, 2026

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71.

Benzinga • Jan 30, 2026